JPRN-UMIN000011990已完成未知
Endocrinological profiles in patients with prostate cancer treated with LHRH antagonist - Endocrinological profiles of LHRH antagonist
Department of Urology, Gunma University Graduate School of Medicine0 个研究点目标入组 50 人开始时间: 2013年10月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
Degarelix reduced serum testosterone levels soon after the first administration. It also reduced serum adrenal androgen levels.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- •1.Patients treated with concomitant anti-androgens. 2.Patients treated with concomitant medicines that affect serum sex hormone levels.
研究者
相似试验
Unknown
2 期
Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)Prostate NeoplasmNCT01630967British Columbia Cancer Agency40
已完成
不适用
Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate CancerProstatic AdenocarcinomaProstate CancerNCT01542021Memorial Sloan Kettering Cancer Center41
终止
1 期
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate CancerCastrate-resistant Prostate Cancer (CRPC)Androgen-insensitive Prostate CancerHormone-refractory Prostate CancerProstate CancerMetastatic DiseaseProstatic NeoplasmsNCT01020305Sandy Srinivas5
已完成
2 期
Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate CancerProstate CancerNCT01491971Ferring Pharmaceuticals76
已完成
不适用
Effect of dutasteride for relieving benign prostatic obstructioBenign Prostatic HyperplasiaJPRN-UMIN000004454Department of Urology, Nagoya University School of Medicine60